Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.51 |
| ▸ | PPARA | Q07869 | 6/20 | 0.51 |
| ▸ | PPARD | Q03181 | 5/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5721701 | 1.00 | PPARG (0.51) | PPARGPPARAPPARDCYP2D6EPHX2 | |
| SCHEMBL3960321 | 1.00 | PPARG (0.51) | PPARGPPARAPPARDCYP2D6EPHX2 | |
| SCHEMBL5372547 | 1.00 | PPARG (0.51) | PPARGPPARAPPARDCYP2D6EPHX2 | |
| SCHEMBL3960715 | 0.84 | ALDH1A1 (0.60) | PPARGPPARAPPARDMEN1ALDH1A1 | |
| SCHEMBL3960707 | 0.84 | ALDH1A1 (0.60) | PPARGPPARAPPARDMEN1ALDH1A1 | |
| SCHEMBL3968494 | 0.84 | ALDH1A1 (0.60) | PPARGPPARAPPARDMEN1ALDH1A1 | |
| SCHEMBL5358355 | 0.84 | ALDH1A1 (0.60) | PPARGPPARAPPARDMEN1ALDH1A1 | |
| SCHEMBL3968491 | 0.84 | ALDH1A1 (0.60) | PPARGPPARAPPARDMEN1ALDH1A1 | |
| SCHEMBL3965041 | 0.81 | PPARG (0.51) | PPARGPPARAPPARDMEN1LMNA | |
| SCHEMBL3965050 | 0.81 | PPARG (0.51) | PPARGPPARAPPARDMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | claimed |
| EP-1676833-A1 | Propionic acid derivatives useful in the treatment of lipid disorders | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | claimed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | claimed |
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | US | claimed |
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-20070244198-A1 | Carboxylic Derivatives | LI LANNA | 2007-10-18 | — | — | US | disclosed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060258866-A1 | Carboxylic derivates | ASTRAZENECA AB, A SWEDEN CORPORATION | 2006-11-16 | — | — | US | disclosed |
| EP-1676833-A1 | Propionic acid derivatives useful in the treatment of lipid disorders | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244198-A1 | Carboxylic Derivatives | GPR119, CPT1A, PC | PPARG 56/4885PPARA 138/4885PPARD 84/4885 |
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | GPR119, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 6/4885 |
| US-20060258866-A1 | Carboxylic derivates | GPR119, PC, CPT1A | PPARG 91/4885PPARA 145/4885PPARD 127/4885 |
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | PPARG 228/4885PPARA 346/4885PPARD 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.